Crinetics Pharmaceuticals

We're excited to share preclinical data for a potentially first-in-class, nonpeptide drug conjugate candidate in development for neuroendocrine tumors. Join us at 5:15 pm CT to discover our latest research. If interested in more information on our clinical trial program, contact us here: https://lnkd.in/gqwdFKX8

Be part of the conversation at the 2024 NANETS NET Symposium and learn more about our exciting research updates. Stop by the Crinetics Symposium from 12:15-1:15 pm CT in Salon E to learn about our nonpeptide drug conjugate platform and Phase 3 trial details for our carcinoid syndrome candidate. If interested in more information on our clinical trial program, contact us here: https://lnkd.in/gqwdFKX8 #NeuroendocrineTumor

We are excited to join NANETS for the 2024 Multidisciplinary NET Medical Symposium. This annual event brings together leading experts, researchers, and healthcare professionals to explore the latest advancements in neuroendocrine tumor (NET) diagnosis and treatment. At Crinetics, we’re committed to improving patient outcomes and advancing care in the NET community. We look forward to engaging with colleagues and sharing insights that shape the future of NET treatment.

We’re pleased to welcome Samer Saadeh, General Manager, Europe who joined Crinetics as our first European-based employee. Samer will lead our European organization based in Zug, Switzerland, in the development and commercialization of our medicines in Europe. We look forward to continuing to build our global team.

Sixteen years ago, Crinetics formed as an organization focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors.    Today, we’re proud to continue towards our mission as a premier endocrine-focused company committed to transforming the lives of patients impacted by a wide range of endocrine-related diseases with several lead candidates in various stages of drug development. Check out our evolving pipeline here: https://bit.ly/3XghDQx   #endocrinology #happysweet16 

We’re pleased to announce that Bin Zhang, MD, MSc, has joined Crinetics as Senior Vice President of Oncology and will serve as lead physician for Carcinoid Syndrome and our Nonpeptide drug conjugate (NDC) programs. #NDCs are a new technology developed in-house that may be applicable to a wide range of different cancers. See more on our pipeline here: https://bit.ly/3XghDQx

We will be presenting two abstracts from our in-house discovery and development programs at the 2024 NANETS Symposium next week. The abstracts will showcase our latest pipeline advancements, including preclinical data from our nonpeptide drug conjugate platform and data from our Phase 2 carcinoid syndrome study. Learn more here: https://bit.ly/3Z1P3Tc

#CRNX announces third quarter 2024 earnings. Learn more: https://bit.ly/3YJZrxM

On this #VeteransDay, we proudly recognize the extraordinary contributions and sacrifices made by veterans across the country, including those who continue to make an impact here at Crinetics. We caught up with some of our veterans on their journey from military service to a career in biotech, emphasizing the invaluable qualities veterans contribute to the workforce. Join us in celebrating the incredible impact veterans make in and out of uniform.

Today is World NETs Day. Neuroendocrine tumors (NETs) are complex and often underdiagnosed, making awareness key to early detection. Today, we're sharing important facts to shine a light on this condition and make a difference. We proudly support the NETs patient community by partnering with Neuroendocrine Tumor Research Foundation, Neuroendocrine Cancer Awareness Network Inc. and LACNETS to make a lasting difference. Join us in spreading awareness! #WorldNETsDay #NeuroendocrineTumors